Lupin, a prominent player in the Pharmaceuticals & Drugs industry, has recently received an upgrade to a ‘Buy’ rating from MarketsMOJO as of December 30, 2024. This upgrade is attributed to the company’s robust financial health, highlighted by a low Debt to EBITDA ratio of 1.27 times, indicating a strong ability to manage its debt obligations.

In its latest financial results for September 2024, Lupin reported a net profit growth of 6.7%, marking the eighth consecutive quarter of positive results. The company achieved its highest operating cash flow at Rs 3,648.36 crore and a remarkable return on capital employed (ROCE) of 18.68%. Additionally, the operating profit to interest ratio stands at an impressive 18.91 times.

Lupin’s stock is currently in a bullish technical range, supported by favorable indicators such as MACD and Bollinger Bands. With a return on equity (ROE) of 16.8 and a price-to-book value of 6.7, the stock is considered fairly valued and is trading at a discount compared to historical averages. Over the past year, Lupin has generated a substantial return of 74.57%, significantly outperforming the BSE 500 index.